Trial · NCT01331837
Outcomes18
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Time to First Cardiovascular (CV) Events Adjudication Committee (EAC) (CV-EAC) Adjudicated Event | From baseline up to 4.9 years | Analysis was conducted on the Intention to treat (ITT) population, i.e. all patients randomized who have taken at least one dose of study medication | Months | MEDIAN |
| PRIMARY | Percentage of Patients Reporting a Cardiovascular (CV) Events Adjudication Committee (EAC) (CV-EAC) Adjudicated Event | From baseline up to 4.9 years | Analysis was conducted on the Intention to treat (ITT) population, i.e. all patients randomized who have taken at least one dose of study medication | Percentage of patients with event | NUMBER |
| PRIMARY | Time to First CV-EAC Adjudicated Event - Sensitivity Analysis | From Baseline up to 4.9 years | Analyses was conducted on the On-treatment (OT) population, i.e. patients who switched from randomized treatment were censored at the time of treatment switching. | Months | MEDIAN |
| PRIMARY | Percentage of Patients With a CV-EAC Adjudicated Event - Sensitivity Analysis | From Baseline up to 4.9 years | Analyses was conducted on the On-treatment (OT) population, i.e. patients who switched from randomized treatment were censored at the time of treatment switching. | Percentage of patients with event | NUMBER |
| PRIMARY | Time to First CV-EAC Adjudicated Event Excluding Undetermined Cause of Death - Sensitivity Analysis | From baseline up to 4.9 years | Analysis was conducted on the ITT population | Months | MEDIAN |
| PRIMARY | Percentage of Patients With a CV-EAC Adjudicated Event Excluding Undetermined Cause of Death - Sensitivity Analysis | From baseline up to 4.9 years | Analysis was conducted on the ITT population | Percentage of patients with event | NUMBER |
| PRIMARY | Time to First CV-EAC Adjudicated Event Before Last Direct Contact Date | From Baseline up to 4.9 years | Analysis was conducted on the ITT population | Months | MEDIAN |
| PRIMARY | Percentage of Participants With a CV-EAC Adjudicated Event Before Last Direct Contact Date | From Baseline up to 4.9 years | Analysis was conducted on the ITT population | Percentage of participants with event | NUMBER |
| SECONDARY | The Time to First Occurrence of an Expanded CV Composite Endpoint | From baseline up to 4.9 years | Analysis was conducted on the ITT population. | Months | MEDIAN |
| SECONDARY | Percentages of Participants With an Expanded CV Composite Endpoint | From baseline up to 4.9 years | Analysis was conducted on the ITT population. | Percentages of participants | NUMBER |
| SECONDARY | Time to First Occurrence of Individual Component of Primary Endpoint: Non-fatal Myocardial Infarction | From baseline up to 4.9 years | Anlysis was conducted on the ITT population. | Months | MEDIAN |
| SECONDARY | Percentage of Patients With Individual Component of Primary Endpoint: Non-fatal Myocardial Infarction | From baseline up to 4.9 years | Anlysis was conducted on the ITT population | Percentage of patients | NUMBER |
| SECONDARY | Time to First Occurrence of Individual Component of Primary Endpoint: Cardiovascular Death | From baseline up to 4.9 years | Analysis was conducted on the ITT population | Months | MEDIAN |
| SECONDARY | Percentage of Patients With Individual Component of Primary Endpoint: Cardiovascular Death | From baseline up to 4.9 years | Analysis was conducted on the ITT population | Percentage of patients | NUMBER |
| SECONDARY | Time to First Occurrence of Individual Component of Primary Endpoint: Non-fatal Stroke | From baseline up to 4.9 years | Analysis was conducted on the ITT population | Months | MEDIAN |
| SECONDARY | Percentage of Patients With Individual Component of Primary Endpoint: Non-fatal Stroke | From baseline up to 4.9 years | Analysis was conducted on the ITT population | Percentage of patients | NUMBER |
| SECONDARY | Time to First Occurrence of Individual Component of Primary Endpoint: All-cause Mortality | From baseline up to 4.9 years | Analysis was conducted on the ITT population. | Months | MEDIAN |
| SECONDARY | Percentage of Patients With Individual Component of Primary Endpoint: All-cause Mortality | From baseline up to 4.9 years | Analysis was conducted on the ITT population. | Percentage of patients | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01331837/outcomes